About: Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Sector: Healthcare
Industry: Biotechnology
Latest price: $40.50 (+0.80%)
Status: deslistada — removed_from_provider. Este ativo não é mais negociado; são exibidos dados históricos.
CNTA NASDAQ Centessa Pharmaceuticals PLC ADR
Centessa Pharmaceuticals PLC ADR share price
Atividade de preço de CNTA
Último preço
Variação (24h)
USD
Volume
-
Volume (média 4 sem.)
-
Fechamento anterior
N/D
Último negócio
CNTA price performance
quote.marketSignals